首页 > 最新文献

Alimentary Pharmacology & Therapeutics最新文献

英文 中文
Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance 信:加强肝硬化管理--社工在支持非酒精性脂肪肝监测中的关键作用
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-09 DOI: 10.1111/apt.18245
Senlin Ye, Jinli Liu, Ruyi Zhou
<p>We read with great interest the study by Tran et al.<span><sup>1</sup></span> which offers valuable insights into the changing epidemiology of cirrhosis, particularly regarding variations in aetiology and outcomes over the past two decades. These findings are crucial for clinical practice and public health policy. However, we identified some limitations that warrant further discussion.</p><p>Firstly, the study relies on administrative claims data, which, despite its comprehensiveness, is prone to misclassification and undercoding.<span><sup>2</sup></span> This can lead to inaccurate estimates of cirrhosis aetiology prevalence and misinterpretations of disease trends. Coding inaccuracies or delays in data collection may result in the underreporting of certain aetiologies. To address this, future research should integrate additional data sources, such as electronic health records and patient registries, to improve patient characterisation and prevalence estimates' accuracy.<span><sup>3, 4</sup></span></p><p>Additionally, the study focusses solely on privately insured patients, introducing a risk of selection bias. This cohort may not represent the broader US population, particularly the uninsured or underinsured, who often experience poorer health outcomes. This bias could result in findings that do not fully reflect the characteristics of the entire US cirrhosis population. Future studies should expand the dataset to include publicly insured (e.g. Medicaid and Medicare)<span><sup>5</sup></span> and uninsured individuals.<span><sup>6</sup></span> Employing weighted or stratified analyses could also help correct biases and enhance the generalisability of the findings.</p><p>Thirdly, the authors also did not account for the impact of lifestyle factors, such as diet, physical activity and alcohol consumption, on cirrhosis progression and outcomes.<span><sup>7-10</sup></span> These factors are critical in understanding the natural history of cirrhosis, particularly for conditions like non-alcoholic fatty liver disease (NAFLD). Including data on lifestyle factors, perhaps through patient surveys or integration with other datasets, would allow for a more nuanced analysis of risk factors and potential interventions.</p><p>Finally, while the study emphasises that NAFLD has become a leading cause of cirrhosis and underscores the need for awareness and monitoring, the development of standardised guidelines for the surveillance and management of NAFLD patients is crucial. Social workers play a pivotal role in this context; they can drive comprehensive community health education initiatives to raise awareness of NAFLD risk factors and prevention strategies. Moreover, they can assist patients in overcoming economic, geographic and cultural barriers to ensure access to timely medical care and regular health monitoring, particularly in high-risk communities. By implementing community-level health screening programmes, social workers can facilitate the early de
本文链接至 Tran 等人的论文。要查看这些文章,请访问 https://doi.org/10.1111/apt.18024 和 https://doi.org/10.1111/apt.18265。
{"title":"Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance","authors":"Senlin Ye,&nbsp;Jinli Liu,&nbsp;Ruyi Zhou","doi":"10.1111/apt.18245","DOIUrl":"10.1111/apt.18245","url":null,"abstract":"&lt;p&gt;We read with great interest the study by Tran et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; which offers valuable insights into the changing epidemiology of cirrhosis, particularly regarding variations in aetiology and outcomes over the past two decades. These findings are crucial for clinical practice and public health policy. However, we identified some limitations that warrant further discussion.&lt;/p&gt;&lt;p&gt;Firstly, the study relies on administrative claims data, which, despite its comprehensiveness, is prone to misclassification and undercoding.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; This can lead to inaccurate estimates of cirrhosis aetiology prevalence and misinterpretations of disease trends. Coding inaccuracies or delays in data collection may result in the underreporting of certain aetiologies. To address this, future research should integrate additional data sources, such as electronic health records and patient registries, to improve patient characterisation and prevalence estimates' accuracy.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Additionally, the study focusses solely on privately insured patients, introducing a risk of selection bias. This cohort may not represent the broader US population, particularly the uninsured or underinsured, who often experience poorer health outcomes. This bias could result in findings that do not fully reflect the characteristics of the entire US cirrhosis population. Future studies should expand the dataset to include publicly insured (e.g. Medicaid and Medicare)&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; and uninsured individuals.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Employing weighted or stratified analyses could also help correct biases and enhance the generalisability of the findings.&lt;/p&gt;&lt;p&gt;Thirdly, the authors also did not account for the impact of lifestyle factors, such as diet, physical activity and alcohol consumption, on cirrhosis progression and outcomes.&lt;span&gt;&lt;sup&gt;7-10&lt;/sup&gt;&lt;/span&gt; These factors are critical in understanding the natural history of cirrhosis, particularly for conditions like non-alcoholic fatty liver disease (NAFLD). Including data on lifestyle factors, perhaps through patient surveys or integration with other datasets, would allow for a more nuanced analysis of risk factors and potential interventions.&lt;/p&gt;&lt;p&gt;Finally, while the study emphasises that NAFLD has become a leading cause of cirrhosis and underscores the need for awareness and monitoring, the development of standardised guidelines for the surveillance and management of NAFLD patients is crucial. Social workers play a pivotal role in this context; they can drive comprehensive community health education initiatives to raise awareness of NAFLD risk factors and prevention strategies. Moreover, they can assist patients in overcoming economic, geographic and cultural barriers to ensure access to timely medical care and regular health monitoring, particularly in high-risk communities. By implementing community-level health screening programmes, social workers can facilitate the early de","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18245","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? 社论:食品中的乳化剂和增稠剂会改变肠道渗透性吗?
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-09 DOI: 10.1111/apt.18222
Joshua Reid, Robin Spiller
<p>Changing from a traditional home-cooked diet to a ‘Western diet’, high in ultra-processed foods (UPFs), may play a role in the recent increase in Crohn's disease observed in many countries where it was previously rare.<span><sup>1, 2</sup></span> Fitzpatrick et al hypothesised that diets high in UPFs increase gut permeability, allowing access of pro-inflammatory bacterial products such as lipopolysaccharide (LPS) to the immune system leading to IBD.<span><sup>3</sup></span> Studying this involved creating a high emulsifier diet (HED) and a low emulsifier diet (LED), with 70% and 29% calories from UPFs, respectively.<span><sup>4</sup></span> They identified 30 different emulsifiers and thickeners in the HED, which have very varied chemical structures and properties with the common aim of preventing phase separation. For example, surfactant-type emulsifiers (e.g. soy lecithin) lower surface tension, whereas biopolymer-type thickeners (e.g. pectin) increase viscosity.<span><sup>5</sup></span> The dominant thickener in the HED was acetylated distarch adipate (E1422), accounting for 60% (1614/2815 mg/day) of total emulsifier/thickener content. Acetylated starch is a resistant starch, which increases colonic short-chain fatty acids although extensive human feeding studies do not show any deleterious effect.<span><sup>6</sup></span> By contrast, the emulsifier polysorbate 80 was present in minute amounts (0.00002 mg/day) with other additives in the range 5–100 mg/day each.</p><p>The HED and LED diets were fed in a randomised single-blinded, cross-over study to assess the effect on the upper small bowel permeability as assessed by the lactulose/rhamnose ratio (LRR)<span><sup>7</sup></span> and blood levels of LPS. The results were somewhat surprising in that the HED actually decreased the LRR and LPS. However, when stressed, those on the HED had a rise in LRR while those on the LED had a fall. Unfortunately, there was an order-effect meaning this stress-induced increase in LRR on the HED was only observed if HED was consumed first. While the authors should be congratulated on tackling an important question, the results raise more questions than answers. The HED initially appeared to decrease LRR; was this due to a response to injury incurred on starting the HED, or does it reflect adherence of fibres consumed the night before to the mucus layer impeding paracellular uptake of a large molecule like lactulose?</p><p>Pre-clinical studies using IBD models such as that of Ogulur et al.<span><sup>8</sup></span> have tended to focus on somewhat atypical emulsifiers, which are actually consumed in very small amounts. What this study teaches us is that future studies should test substances that predominate in UPFs and have a specific mechanism, for example emulsifiers such as lecithins<span><sup>9, 10</sup></span> or thickeners such as modified starch. Human studies should avoid a cross-over design and be less ambitious, using just one agent, such as acetylate
1,2菲茨帕特里克(Fitzpatrick)等人推测,高乳化剂饮食会增加肠道渗透性,使脂多糖(LPS)等促炎性细菌产物进入免疫系统,导致肠道疾病。他们在高乳化剂膳食(HED)和低乳化剂膳食(LED)中发现了 30 种不同的乳化剂和增稠剂,这些乳化剂和增稠剂的化学结构和性质各不相同,其共同目的是防止相分离。例如,表面活性剂型乳化剂(如大豆卵磷脂)可降低表面张力,而生物聚合物型增稠剂(如果胶)可增加粘度。5 HED 中最主要的增稠剂是乙酰化己二酸二淀粉(E1422),占乳化剂/增稠剂总含量的 60%(1614/2815 毫克/天)。乙酰化淀粉是一种抗性淀粉,会增加结肠短链脂肪酸,尽管大量人体喂养研究并未显示出任何有害影响。相比之下,乳化剂聚山梨醇酯 80 的用量很小(0.00002 毫克/天),其他添加剂的用量在 5-100 毫克/天之间。HED 日粮和 LED 日粮进行了随机单盲交叉研究,以评估通过乳糖/鼠李糖比率(LRR)7 和血液中 LPS 水平评估的对上小肠通透性的影响。结果有些出人意料,因为 HED 实际上降低了 LRR 和 LPS。然而,当受到压力时,服用 HED 的人 LRR 上升,而服用 LED 的人 LRR 下降。不幸的是,存在一种顺序效应,即只有首先消耗 HED 的情况下,才能观察到 HED 的 LRR 因压力而增加。虽然应该祝贺作者解决了一个重要的问题,但结果提出的问题多于答案。HED最初似乎降低了LRR;这是由于对开始摄入HED时所受伤害的反应,还是反映了前一天晚上摄入的纤维粘附在粘液层上,阻碍了像乳糖这样的大分子的旁细胞摄入?这项研究给我们的启示是,未来的研究应测试在 UPF 中占主导地位并具有特定机制的物质,例如卵磷脂9、10 等乳化剂或变性淀粉等增稠剂。人体研究应避免采用交叉研究的设计,而应降低要求,只使用一种制剂,如乙酰化淀粉或大豆卵磷脂作为干预措施。这样的研究更有可能就特定乳化剂或增稠剂在作为正常饮食的一部分时是否会显著改变人体肠道渗透性得出明确的答案,而这一点目前还不清楚:构思;写作--审阅和编辑。罗宾-斯皮勒JR声明没有利益冲突。RS获得了赛诺菲和雀巢公司的研究资助,并且是Enterobiotix公司的顾问。要查看这些文章,请访问 https://doi.org/10.1111/apt.18172 和 https://doi.org/10.1111/apt.18266。
{"title":"Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability?","authors":"Joshua Reid,&nbsp;Robin Spiller","doi":"10.1111/apt.18222","DOIUrl":"10.1111/apt.18222","url":null,"abstract":"&lt;p&gt;Changing from a traditional home-cooked diet to a ‘Western diet’, high in ultra-processed foods (UPFs), may play a role in the recent increase in Crohn's disease observed in many countries where it was previously rare.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; Fitzpatrick et al hypothesised that diets high in UPFs increase gut permeability, allowing access of pro-inflammatory bacterial products such as lipopolysaccharide (LPS) to the immune system leading to IBD.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Studying this involved creating a high emulsifier diet (HED) and a low emulsifier diet (LED), with 70% and 29% calories from UPFs, respectively.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; They identified 30 different emulsifiers and thickeners in the HED, which have very varied chemical structures and properties with the common aim of preventing phase separation. For example, surfactant-type emulsifiers (e.g. soy lecithin) lower surface tension, whereas biopolymer-type thickeners (e.g. pectin) increase viscosity.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; The dominant thickener in the HED was acetylated distarch adipate (E1422), accounting for 60% (1614/2815 mg/day) of total emulsifier/thickener content. Acetylated starch is a resistant starch, which increases colonic short-chain fatty acids although extensive human feeding studies do not show any deleterious effect.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; By contrast, the emulsifier polysorbate 80 was present in minute amounts (0.00002 mg/day) with other additives in the range 5–100 mg/day each.&lt;/p&gt;&lt;p&gt;The HED and LED diets were fed in a randomised single-blinded, cross-over study to assess the effect on the upper small bowel permeability as assessed by the lactulose/rhamnose ratio (LRR)&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; and blood levels of LPS. The results were somewhat surprising in that the HED actually decreased the LRR and LPS. However, when stressed, those on the HED had a rise in LRR while those on the LED had a fall. Unfortunately, there was an order-effect meaning this stress-induced increase in LRR on the HED was only observed if HED was consumed first. While the authors should be congratulated on tackling an important question, the results raise more questions than answers. The HED initially appeared to decrease LRR; was this due to a response to injury incurred on starting the HED, or does it reflect adherence of fibres consumed the night before to the mucus layer impeding paracellular uptake of a large molecule like lactulose?&lt;/p&gt;&lt;p&gt;Pre-clinical studies using IBD models such as that of Ogulur et al.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; have tended to focus on somewhat atypical emulsifiers, which are actually consumed in very small amounts. What this study teaches us is that future studies should test substances that predominate in UPFs and have a specific mechanism, for example emulsifiers such as lecithins&lt;span&gt;&lt;sup&gt;9, 10&lt;/sup&gt;&lt;/span&gt; or thickeners such as modified starch. Human studies should avoid a cross-over design and be less ambitious, using just one agent, such as acetylate","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18222","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial 信双膦酸盐对肝硬化患者的疗效--模拟临床试验
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-09 DOI: 10.1111/apt.18257
Mingsi Zhang, Yunmeng Nie
<p>We read the article by Tapper et al.<span><sup>1</sup></span> with great interest and commend the authors for their innovative and clinically valuable research focus. The study, which used US Medicare data and an emulated clinical trial design, provides valuable insights into the role of bisphosphonates in reducing fracture risk in cirrhotic patients. The results suggest that bisphosphonates are effective in reducing fracture risk in cirrhotic patients and highlight the need to monitor osteoporosis in this population. However, several concerns limit the study's applicability.</p><p>First, bisphosphonates typically require long-term administration to sustain improvements in bone density and reduce fracture risk.<span><sup>2, 3</sup></span> The effectiveness of bisphosphonates depends largely on patient adherence. Irregular medication intake, early discontinuation, or not following the prescribed dosage can diminish the therapy's benefits, leading to less effective outcomes. The study does not adequately address the role of adherence, which is crucial to determining bisphosphonates effectiveness. This shortcoming limits the applicability of the findings. The inclusion of adherence factors in follow-up design should be conducted to provide more clinically relevant insights into the management of osteoporosis in cirrhotic patients.</p><p>Second, the data came entirely from Medicare, a government-funded healthcare program for individuals over 65 with disabilities or haemodialysis. This implies that the study population predominantly consists of elderly individuals. There were significant differences in baseline bone density and fracture recovery between elderlies and younger patients.<span><sup>4</sup></span> Therefore, data on the efficacy of bisphosphonates, particularly in reducing fracture risk, may not be applicable to patients with cirrhosis of the liver in young and middle-aged patients. Future studies should aim to broaden the sample demographic, especially by including young cirrhotic patients, to assess the differential efficacy of bisphosphonates in different age groups. This approach will help determine whether bisphosphonate therapy provides the same fracture prevention benefits for cirrhotic patients in all age groups, enhancing the generalizability and applicability of the results.</p><p>Third, cirrhotic patients are often accompanied by multiple comorbidities, such as diabetes, chronic kidney disease, and cardiovascular diseases, and independently increases the risk of fracture.<span><sup>5</sup></span> In addition, these conditions often require drugs such as corticosteroids and proton pump inhibitors, which negatively impact bone metabolism and further increase the risk of fracture.<span><sup>6, 7</sup></span> While the study attempted to adjust to these factors, this adjustment may not fully take into account all comorbidities, especially if there is an interaction between them.</p><p>Despite these limitations, the study makes a
本文链接至 Tapper 等人的论文。要查看这些文章,请访问 https://doi.org/10.1111/apt.18127 和 https://doi.org/10.1111/apt.18259。
{"title":"Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial","authors":"Mingsi Zhang,&nbsp;Yunmeng Nie","doi":"10.1111/apt.18257","DOIUrl":"10.1111/apt.18257","url":null,"abstract":"&lt;p&gt;We read the article by Tapper et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; with great interest and commend the authors for their innovative and clinically valuable research focus. The study, which used US Medicare data and an emulated clinical trial design, provides valuable insights into the role of bisphosphonates in reducing fracture risk in cirrhotic patients. The results suggest that bisphosphonates are effective in reducing fracture risk in cirrhotic patients and highlight the need to monitor osteoporosis in this population. However, several concerns limit the study's applicability.&lt;/p&gt;&lt;p&gt;First, bisphosphonates typically require long-term administration to sustain improvements in bone density and reduce fracture risk.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; The effectiveness of bisphosphonates depends largely on patient adherence. Irregular medication intake, early discontinuation, or not following the prescribed dosage can diminish the therapy's benefits, leading to less effective outcomes. The study does not adequately address the role of adherence, which is crucial to determining bisphosphonates effectiveness. This shortcoming limits the applicability of the findings. The inclusion of adherence factors in follow-up design should be conducted to provide more clinically relevant insights into the management of osteoporosis in cirrhotic patients.&lt;/p&gt;&lt;p&gt;Second, the data came entirely from Medicare, a government-funded healthcare program for individuals over 65 with disabilities or haemodialysis. This implies that the study population predominantly consists of elderly individuals. There were significant differences in baseline bone density and fracture recovery between elderlies and younger patients.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Therefore, data on the efficacy of bisphosphonates, particularly in reducing fracture risk, may not be applicable to patients with cirrhosis of the liver in young and middle-aged patients. Future studies should aim to broaden the sample demographic, especially by including young cirrhotic patients, to assess the differential efficacy of bisphosphonates in different age groups. This approach will help determine whether bisphosphonate therapy provides the same fracture prevention benefits for cirrhotic patients in all age groups, enhancing the generalizability and applicability of the results.&lt;/p&gt;&lt;p&gt;Third, cirrhotic patients are often accompanied by multiple comorbidities, such as diabetes, chronic kidney disease, and cardiovascular diseases, and independently increases the risk of fracture.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; In addition, these conditions often require drugs such as corticosteroids and proton pump inhibitors, which negatively impact bone metabolism and further increase the risk of fracture.&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt; While the study attempted to adjust to these factors, this adjustment may not fully take into account all comorbidities, especially if there is an interaction between them.&lt;/p&gt;&lt;p&gt;Despite these limitations, the study makes a ","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18257","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance: Authors' reply 信:加强肝硬化管理--社工在支持非酒精性脂肪肝监测中的关键作用:作者回复
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-09 DOI: 10.1111/apt.18265
Sally Tran, Linda Henry, Mindie H. Nguyen
<p>We thank Ye et al. for their thoughtful comments on our recent study.<span><sup>1, 2</sup></span> While we agree with their suggestions for expansion of the study cohort characteristics using other databases to augment our study, this was beyond the scope of this study but is something that can be considered for future studies. In this context, we did acknowledge the limitations of our study to include the potential for undercoding or miscoding of cirrhosis and that our study population was only those who had private insurance which may limit the generalizability of our study results.<span><sup>1</sup></span> However, as Ye et al. pointed out, those from low income and low education backgrounds are more likely to have chronic liver disease (CLD) and cirrhosis, which with the addition of Medicaid data, would most likely have made our trends even more pronounced especially for nonalcoholic fatty liver disease (now known as metabolic dysfunction-associated steatotic liver disease, MASLD) and alcohol-related liver disease (ALD).<span><sup>3</sup></span> As has been recently reported, MASLD and ALD are the two main drivers of CLD with those from low income and low education more likely to have an increased burden of disease.<span><sup>4</sup></span></p><p>On the other hand, a major strength of the study was our ethnic breakdown by liver disease. This information can be used by communities to develop targeted interventions for the liver disease most likely to be prevalent in their communities.<span><sup>5</sup></span> While we also agree that social workers can play a pivotal role in community-based screening, at this time, screening for MASLD is not cost effective.<span><sup>6-8</sup></span> Nonetheless, screening for what is considered high risk MASLD, those with fibrosis stage 2 or greater, may be cost effective and help decrease disease progression to cirrhosis and other adverse outcomes.<span><sup>8</sup></span> However, the identification of those with high risk MASLD has many barriers to include low awareness, lack of available non-invasive tests and, until recently, lack of treatment outside of diet and exercise.<span><sup>7</sup></span> As a new drug, resmetirom has now come to market for treatment of MASLD with fibrosis stages 2 and 3, there is a renewed interest on identifying high risk patients.<span><sup>9</sup></span> Therefore, it is apparent that community-based actions for MASLD should be centred on persons most at risk for having MASLD (being obese, having type 2 diabetes, presence of metabolic syndrome) to increase awareness of this CLD and what interventions are now available to help individuals who may be at risk of having MASLD in order for them to seek care for further evaluation.<span><sup>10</sup></span></p><p>We appreciate Ye et. al.'s article highlighting the importance of all healthcare workers working together to not only reverse the growing prevalence of MASLD and its adverse outcomes but also of other CLDs that may be
本文链接至 Tran 等人的论文。要查看这些文章,请访问 https://doi.org/10.1111/apt.18024 和 https://doi.org/10.1111/apt.18245。
{"title":"Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance: Authors' reply","authors":"Sally Tran,&nbsp;Linda Henry,&nbsp;Mindie H. Nguyen","doi":"10.1111/apt.18265","DOIUrl":"10.1111/apt.18265","url":null,"abstract":"&lt;p&gt;We thank Ye et al. for their thoughtful comments on our recent study.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; While we agree with their suggestions for expansion of the study cohort characteristics using other databases to augment our study, this was beyond the scope of this study but is something that can be considered for future studies. In this context, we did acknowledge the limitations of our study to include the potential for undercoding or miscoding of cirrhosis and that our study population was only those who had private insurance which may limit the generalizability of our study results.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; However, as Ye et al. pointed out, those from low income and low education backgrounds are more likely to have chronic liver disease (CLD) and cirrhosis, which with the addition of Medicaid data, would most likely have made our trends even more pronounced especially for nonalcoholic fatty liver disease (now known as metabolic dysfunction-associated steatotic liver disease, MASLD) and alcohol-related liver disease (ALD).&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; As has been recently reported, MASLD and ALD are the two main drivers of CLD with those from low income and low education more likely to have an increased burden of disease.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;On the other hand, a major strength of the study was our ethnic breakdown by liver disease. This information can be used by communities to develop targeted interventions for the liver disease most likely to be prevalent in their communities.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; While we also agree that social workers can play a pivotal role in community-based screening, at this time, screening for MASLD is not cost effective.&lt;span&gt;&lt;sup&gt;6-8&lt;/sup&gt;&lt;/span&gt; Nonetheless, screening for what is considered high risk MASLD, those with fibrosis stage 2 or greater, may be cost effective and help decrease disease progression to cirrhosis and other adverse outcomes.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; However, the identification of those with high risk MASLD has many barriers to include low awareness, lack of available non-invasive tests and, until recently, lack of treatment outside of diet and exercise.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; As a new drug, resmetirom has now come to market for treatment of MASLD with fibrosis stages 2 and 3, there is a renewed interest on identifying high risk patients.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; Therefore, it is apparent that community-based actions for MASLD should be centred on persons most at risk for having MASLD (being obese, having type 2 diabetes, presence of metabolic syndrome) to increase awareness of this CLD and what interventions are now available to help individuals who may be at risk of having MASLD in order for them to seek care for further evaluation.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;We appreciate Ye et. al.'s article highlighting the importance of all healthcare workers working together to not only reverse the growing prevalence of MASLD and its adverse outcomes but also of other CLDs that may be ","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18265","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply 社论:食品中的乳化剂和增稠剂--它们会改变肠道渗透性吗?作者回复
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-09 DOI: 10.1111/apt.18266
Jessica A. Fitzpatrick, Peter R. Gibson, Emma P. Halmos
<p>The relationship between dietary emulsifiers and Crohn's disease is intriguing and warrants continuing exploration. It may present information not only on pathogenesis and preventive strategies,<span><sup>1</sup></span> but also on dietary advice to control inflammation in patients with established Crohn's disease.<span><sup>2</sup></span> The emulsifier story has excited many. The European Society for Clinical Nutrition and the International Organisation for the Study of IBD have concerningly translated preclinical data to ‘evidence-based’ clinical advice for patients with Crohn's disease to avoid foods with added emulsifiers.<span><sup>3, 4</sup></span> This dietary advice is not simple to implement for people living with Crohn's disease, since there are over 40 different emulsifiers in our food supply identified on ingredients lists on packaged food as either additive numbers or in expanded form. Over-restriction of many packaged foods will have considerable effects on food-related quality of life and psychosocial interactions, and is impractical in our modern world.</p><p>The editorial from Reid and Spiller<span><sup>5</sup></span> on our study regarding the effects of diets varying in emulsifier content on intestinal barrier function<span><sup>6</sup></span> has highlighted the gulf between the preclinical IBD models and how to establish the type of evidence that can be validly translated to dietary recommendations. Reid and Spiller recommend a scientist's reductionist approach to study single emulsifiers to determine their biological effects. We have taken the clinically translatable dietetic approach to studying emulsifiers as a group in the existing food supply. Both approaches are required for progressing our understanding of emulsifiers impacting Crohn's disease, but there are advantages to the dietetic approach. First, the emulsifiers examined represent what is actually in our food supply as opposed to choosing what Reid and Spiller correctly described as ‘obscure’ emulsifiers. Second, the doses to which research subjects are to be exposed in a high-emulsifier diet are those of the ‘real world’,<span><sup>7</sup></span> as opposed to the large, pharmacological doses of specific emulsifiers that have been administered to mice and humans in studies to date.<span><sup>8-10</sup></span> Translating the effects of megadoses to those that might be reasonably consumed in a high-emulsifier diet is flawed and dangerous. More care in dosing has to be taken if the results are to be meaningfully applied to dietary management. Third, the concept that individual emulsifiers will work similarly when not incorporated in food and not interact with other emulsifiers is oversimplified and untested. Fourth, as Reid and Spiller commented, the heterogeneity in emulsifier action in the gut is important to consider, with some thickeners potentially having a beneficial effect.</p><p>Studying intake of emulsifiers as they are found in the food supply enables
膳食乳化剂与克罗恩病之间的关系令人好奇,值得继续探索。它不仅可以提供有关发病机理和预防策略的信息1 ,还可以提供有关已确诊克罗恩病患者控制炎症的饮食建议2。欧洲临床营养学会(European Society for Clinical Nutrition)和国际肠道疾病研究组织(International Organisation for the Study of IBD)将临床前数据转化为 "循证 "临床建议,要求克罗恩病患者避免食用添加乳化剂的食品,这令人担忧。Reid 和 Spiller5 就我们关于乳化剂含量不同的膳食对肠屏障功能影响的研究发表的社论6 强调了临床前 IBD 模型与如何建立可有效转化为膳食建议的证据类型之间的鸿沟。Reid 和 Spiller 建议科学家采用还原法研究单一乳化剂,以确定其生物效应。我们采用了可临床转化的营养学方法,将乳化剂作为现有食品供应中的一组乳化剂进行研究。这两种方法对于加深我们对影响克罗恩病的乳化剂的了解都是必要的,但营养学方法有其优势。首先,所研究的乳化剂代表了食品供应中的实际情况,而不是选择里德和斯皮勒正确描述的 "模糊 "乳化剂。其次,研究对象在高乳化剂膳食中接触的剂量是 "真实世界 "7 中的剂量,而不是迄今为止在研究中对小鼠和人类施用的大剂量、药理学剂量的特定乳化剂。如果要将研究结果有意义地应用于膳食管理,就必须在剂量上更加谨慎。第三,认为单个乳化剂在未加入食物中时也会发挥类似作用,并且不会与其他乳化剂发生相互作用的概念过于简单,也未经检验。第四,正如里德和斯皮勒所评论的,乳化剂在肠道中的作用具有异质性,有些增稠剂可能会产生有益的影响,这一点必须加以考虑。研究食品供应中乳化剂的摄入量,可以从整体上研究乳化剂的生物效应,并确定在膳食中尽量减少乳化剂的影响。不过,这两种研究方法都需要,以确定违规的罪魁祸首或有益的乳化剂。为了避免在没有证据的情况下将食物成分妖魔化,需要在精心设计的饮食控制人体试验中评估临床前研究提出的因果关系,然后在克罗恩病患者身上进行期待已久的评估。现在,如果你吃了冰淇淋,请不要感到内疚!杰西卡-A-菲茨帕特里克(Jessica A. Fitzpatrick):写作--审阅和编辑;构思。彼得-R-吉布森:写作--审阅和编辑;构思。Emma P. Halmos:本文与菲茨帕特里克等人的论文链接。要查看这些文章,请访问 https://doi.org/10.1111/apt.18172 和 https://doi.org/10.1111/apt.18222。
{"title":"Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply","authors":"Jessica A. Fitzpatrick,&nbsp;Peter R. Gibson,&nbsp;Emma P. Halmos","doi":"10.1111/apt.18266","DOIUrl":"10.1111/apt.18266","url":null,"abstract":"&lt;p&gt;The relationship between dietary emulsifiers and Crohn's disease is intriguing and warrants continuing exploration. It may present information not only on pathogenesis and preventive strategies,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; but also on dietary advice to control inflammation in patients with established Crohn's disease.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The emulsifier story has excited many. The European Society for Clinical Nutrition and the International Organisation for the Study of IBD have concerningly translated preclinical data to ‘evidence-based’ clinical advice for patients with Crohn's disease to avoid foods with added emulsifiers.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt; This dietary advice is not simple to implement for people living with Crohn's disease, since there are over 40 different emulsifiers in our food supply identified on ingredients lists on packaged food as either additive numbers or in expanded form. Over-restriction of many packaged foods will have considerable effects on food-related quality of life and psychosocial interactions, and is impractical in our modern world.&lt;/p&gt;&lt;p&gt;The editorial from Reid and Spiller&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; on our study regarding the effects of diets varying in emulsifier content on intestinal barrier function&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; has highlighted the gulf between the preclinical IBD models and how to establish the type of evidence that can be validly translated to dietary recommendations. Reid and Spiller recommend a scientist's reductionist approach to study single emulsifiers to determine their biological effects. We have taken the clinically translatable dietetic approach to studying emulsifiers as a group in the existing food supply. Both approaches are required for progressing our understanding of emulsifiers impacting Crohn's disease, but there are advantages to the dietetic approach. First, the emulsifiers examined represent what is actually in our food supply as opposed to choosing what Reid and Spiller correctly described as ‘obscure’ emulsifiers. Second, the doses to which research subjects are to be exposed in a high-emulsifier diet are those of the ‘real world’,&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; as opposed to the large, pharmacological doses of specific emulsifiers that have been administered to mice and humans in studies to date.&lt;span&gt;&lt;sup&gt;8-10&lt;/sup&gt;&lt;/span&gt; Translating the effects of megadoses to those that might be reasonably consumed in a high-emulsifier diet is flawed and dangerous. More care in dosing has to be taken if the results are to be meaningfully applied to dietary management. Third, the concept that individual emulsifiers will work similarly when not incorporated in food and not interact with other emulsifiers is oversimplified and untested. Fourth, as Reid and Spiller commented, the heterogeneity in emulsifier action in the gut is important to consider, with some thickeners potentially having a beneficial effect.&lt;/p&gt;&lt;p&gt;Studying intake of emulsifiers as they are found in the food supply enables","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18266","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply 信:社会工作与临床协同作用--优化针对 DGBI 老年人群的健康干预措施:作者回复。
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-08 DOI: 10.1111/apt.18252
Ami D. Sperber, Tamar Freud, Olafur S. Palsson, Shrikant I. Bangdiwala, Magnus Simren

We thank Drs. Chang, Wei and Liu for their interest in our paper on the ageing gastrointestinal tract,1 as expressed in their letter.2 We would like to make a few clarifications in response.

The most important point to clarify is that missing data were not an issue of concern in our analyses, and did not affect the findings. Therefore, the use of multiple imputations and sensitivity analysis suggested by the authors is not relevant to our study. The gastrointestinal symptom data from the 54,127 individuals, whose survey responses we analysed, did not have any missing data points. This reflects one of the strengths of the Internet-based electronic survey methodology we used, where responses can be automatically checked and answers enforced page by page by the survey software in order to prevent missing data.

Chang et al. also commented that it would have been important to include variables in our study on lifestyle factors, socioeconomic factors and chronic comorbidities, as well as doing sub-group analyses by country or centre, in order to reveal disparities in care and to guide tailoring of intervention strategies. We agree that examining healthcare disparities and elucidating ways to improve healthcare related to disorders of gut–brain interaction (DGBI) are important research aims. However, these were not the goals of our study, which explicitly focused on examining whether older individuals in society generally have lower DGBI prevalence rates. However, future investigations of age differences in DGBI would do well to include assessment of lifestyle and socioeconomic factors, as these might be relevant to understanding the causes of reduced DGBI rates with advancing age. In particular, differences between younger and older adults in living conditions, lifestyle and daily stress, as well as generational differences in emotional factors, could play a role. We hope that our paper will spur further studies that can reveal the factors that explain the mysterious universal ageing-related decline in DGBI rates in populations across the world that we described.

Ami D. Sperber: Writing – original draft; conceptualization. Tamar Freud: Writing – review and editing. Olafur S. Palsson: Writing – original draft; conceptualization. Shrikant I. Bangdiwala: Writing – review and editing. Magnus Simren: Writing – review and editing.

This article is linked to Sperber et al papers. To view these articles, visit https://doi.org/10.1111/apt.18103 and https://doi.org/10.1111/apt.18225

我们感谢张博士、魏博士和刘博士在信中对我们关于胃肠道老化的论文1 所表达的兴趣2 。因此,作者提出的多重归因和敏感性分析与我们的研究无关。我们分析了 54127 人的调查回答,其中的胃肠道症状数据没有任何数据点缺失。Chang等人还评论说,在我们的研究中加入生活方式因素、社会经济因素和慢性并发症等变量,并按国家或中心进行分组分析,对于揭示医疗差异和指导干预策略的制定非常重要。我们同意,研究与肠脑互动障碍(DGBI)相关的医疗保健差异和阐明改善医疗保健的方法是重要的研究目标。然而,这些并不是我们的研究目标,我们的研究明确侧重于研究社会中老年人的 DGBI 患病率是否普遍较低。不过,未来对 DGBI 年龄差异的调查最好能包括对生活方式和社会经济因素的评估,因为这些因素可能与了解随着年龄增长 DGBI 患病率降低的原因有关。特别是,年轻人和老年人在生活条件、生活方式和日常压力方面的差异,以及在情感因素方面的代际差异,都可能起到一定的作用。我们希望我们的论文能促进进一步的研究,揭示我们所描述的全球人口中与年龄增长相关的DGBI率下降的神秘因素。塔玛尔-弗洛伊德写作--审阅和编辑。Olafur S. Palsson:写作--初稿;构思。Shrikant I. Bangdiwala:写作--审阅和编辑。马格努斯-西姆伦本文链接到 Sperber 等人的论文。要查看这些文章,请访问 https://doi.org/10.1111/apt.18103 和 https://doi.org/10.1111/apt.18225。
{"title":"Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply","authors":"Ami D. Sperber,&nbsp;Tamar Freud,&nbsp;Olafur S. Palsson,&nbsp;Shrikant I. Bangdiwala,&nbsp;Magnus Simren","doi":"10.1111/apt.18252","DOIUrl":"10.1111/apt.18252","url":null,"abstract":"<p>We thank Drs. Chang, Wei and Liu for their interest in our paper on the ageing gastrointestinal tract,<span><sup>1</sup></span> as expressed in their letter.<span><sup>2</sup></span> We would like to make a few clarifications in response.</p><p>The most important point to clarify is that missing data were not an issue of concern in our analyses, and did not affect the findings. Therefore, the use of multiple imputations and sensitivity analysis suggested by the authors is not relevant to our study. The gastrointestinal symptom data from the 54,127 individuals, whose survey responses we analysed, did not have any missing data points. This reflects one of the strengths of the Internet-based electronic survey methodology we used, where responses can be automatically checked and answers enforced page by page by the survey software in order to prevent missing data.</p><p>Chang et al. also commented that it would have been important to include variables in our study on lifestyle factors, socioeconomic factors and chronic comorbidities, as well as doing sub-group analyses by country or centre, in order to reveal disparities in care and to guide tailoring of intervention strategies. We agree that examining healthcare disparities and elucidating ways to improve healthcare related to disorders of gut–brain interaction (DGBI) are important research aims. However, these were not the goals of our study, which explicitly focused on examining whether older individuals in society generally have lower DGBI prevalence rates. However, future investigations of age differences in DGBI would do well to include assessment of lifestyle and socioeconomic factors, as these might be relevant to understanding the causes of reduced DGBI rates with advancing age. In particular, differences between younger and older adults in living conditions, lifestyle and daily stress, as well as generational differences in emotional factors, could play a role. We hope that our paper will spur further studies that can reveal the factors that explain the mysterious universal ageing-related decline in DGBI rates in populations across the world that we described.</p><p><b>Ami D. Sperber:</b> Writing – original draft; conceptualization. <b>Tamar Freud:</b> Writing – review and editing. <b>Olafur S. Palsson:</b> Writing – original draft; conceptualization. <b>Shrikant I. Bangdiwala:</b> Writing – review and editing. <b>Magnus Simren:</b> Writing – review and editing.</p><p>This article is linked to Sperber et al papers. To view these articles, visit https://doi.org/10.1111/apt.18103 and https://doi.org/10.1111/apt.18225</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Effect of dietary additives on intestinal barrier and acute stress in healthy adults 信:膳食添加剂对健康成年人肠道屏障和急性应激的影响
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-08 DOI: 10.1111/apt.18226
Liqi Li

Fitzpatrick et al.1 examined the influence of high-emulsifier and low-emulsifier diets on intestinal barrier function of healthy people in unstressed and acutely stressed circumstances. Although the study offered important perspectives on the connection between dietary emulsifiers, intestinal barrier function and stress reactions, multiple aspects can be enhanced or explored further.

First, the study's sample comprising 22 healthy adults might restrict the generalisation of the results. A larger and more diverse group of participants, encompassing individuals with different health conditions and demographic characteristics, could boost the external validity of the findings. Second, the study's single-blinded design, where participants are not informed of their dietary allocations, is prone to bias. A double-blind design, where neither participants nor researchers were aware of the dietary interventions, would fortify the internal validity of the study. Additionally, the study's dependence on self-reported dietary adherence might have led to measurement errors. Integrating objective measurements of dietary intake, such as food diaries or biomarkers, could offer more precise data regarding participant compliance. Moreover, the study concentrated on the impacts of emulsifiers and thickeners on intestinal barrier function and stress responses in healthy individuals. It would be advantageous to investigate the long-term consequences of these dietary components, and their potential implications for individuals with pre-existing gastrointestinal disorders, such as inflammatory bowel disease.

In conclusion, although this study has provided valuable information, addressing the aforementioned limitations could improve its validity and furnish a more all-encompassing comprehension of the effects of dietary emulsifiers and thickeners on intestinal barrier function and stress responses.

Liqi Li: Conceptualization; investigation; methodology; writing – review and editing; writing – original draft; validation.

The author declares no conflicts.

This article is linked to Fitzpatrick et al papers. To view these articles, visit https://doi.org/10.1111/apt.18172 and https://doi.org/10.1111/apt.18267.

菲茨帕特里克等人1 研究了高乳化剂和低乳化剂饮食对健康人在无压力和急性压力情况下肠道屏障功能的影响。尽管该研究为膳食乳化剂、肠道屏障功能和应激反应之间的联系提供了重要的视角,但仍有多个方面可以进一步加强或探讨。首先,该研究的样本包括 22 名健康成年人,这可能会限制研究结果的普遍性。首先,该研究的样本由 22 名健康成年人组成,这可能会限制研究结果的普遍性。更大、更多样化的参与者群体,包括不同健康状况和人口特征的个体,可以提高研究结果的外部有效性。其次,该研究的单盲设计,即参与者不知道自己的饮食分配,容易产生偏差。如果采用双盲设计,即参与者和研究人员都不知道饮食干预措施,则可加强研究的内部有效性。此外,该研究依赖于自我报告的饮食依从性可能会导致测量误差。整合饮食摄入量的客观测量方法,如食物日记或生物标志物,可以提供有关参与者依从性的更精确数据。此外,该研究主要关注乳化剂和增稠剂对健康人肠道屏障功能和应激反应的影响。研究这些膳食成分的长期影响及其对患有炎症性肠病等胃肠道疾病的人的潜在影响将是有益的。总之,尽管这项研究提供了有价值的信息,但解决上述局限性可以提高研究的有效性,更全面地了解膳食乳化剂和增稠剂对肠道屏障功能和应激反应的影响。要查看这些文章,请访问 https://doi.org/10.1111/apt.18172 和 https://doi.org/10.1111/apt.18267。
{"title":"Letter: Effect of dietary additives on intestinal barrier and acute stress in healthy adults","authors":"Liqi Li","doi":"10.1111/apt.18226","DOIUrl":"10.1111/apt.18226","url":null,"abstract":"<p>Fitzpatrick et al.<span><sup>1</sup></span> examined the influence of high-emulsifier and low-emulsifier diets on intestinal barrier function of healthy people in unstressed and acutely stressed circumstances. Although the study offered important perspectives on the connection between dietary emulsifiers, intestinal barrier function and stress reactions, multiple aspects can be enhanced or explored further.</p><p>First, the study's sample comprising 22 healthy adults might restrict the generalisation of the results. A larger and more diverse group of participants, encompassing individuals with different health conditions and demographic characteristics, could boost the external validity of the findings. Second, the study's single-blinded design, where participants are not informed of their dietary allocations, is prone to bias. A double-blind design, where neither participants nor researchers were aware of the dietary interventions, would fortify the internal validity of the study. Additionally, the study's dependence on self-reported dietary adherence might have led to measurement errors. Integrating objective measurements of dietary intake, such as food diaries or biomarkers, could offer more precise data regarding participant compliance. Moreover, the study concentrated on the impacts of emulsifiers and thickeners on intestinal barrier function and stress responses in healthy individuals. It would be advantageous to investigate the long-term consequences of these dietary components, and their potential implications for individuals with pre-existing gastrointestinal disorders, such as inflammatory bowel disease.</p><p>In conclusion, although this study has provided valuable information, addressing the aforementioned limitations could improve its validity and furnish a more all-encompassing comprehension of the effects of dietary emulsifiers and thickeners on intestinal barrier function and stress responses.</p><p><b>Liqi Li:</b> Conceptualization; investigation; methodology; writing – review and editing; writing – original draft; validation.</p><p>The author declares no conflicts.</p><p>This article is linked to Fitzpatrick et al papers. To view these articles, visit https://doi.org/10.1111/apt.18172 and https://doi.org/10.1111/apt.18267.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18226","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations 信:社会工作与临床协同作用--优化针对 DGBI 老年人群的健康干预措施。
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-08 DOI: 10.1111/apt.18225
Rui Zhang, Hua Wei, Ming Liu
<p>We were interested in the recent study by Sperber et al.<span><sup>1</sup></span> This explored the prevalence and clinical significance of disorders of gut–brain interaction (DGBI) in the elderly population. It found that despite a lower prevalence than in younger populations, elderly patients still face a significant health burden, particularly with regard to faecal incontinence. Although the study provided valuable insights, we believe that there are still areas for improvement.</p><p>First, despite the authors' efforts to minimise missing data, it remains an unavoidable issue that could impact the accuracy and reliability of the results. This concern is particularly relevant in older populations, where reporting biases such as recall bias and social desirability bias may be more pronounced. We recommend the use of multiple imputation and sensitivity analyses to mitigate these biases and strengthen the robustness of the findings.<span><sup>2</sup></span></p><p>Second, although the study effectively adjusted for key variables such as age, gender, geographic region and symptom severity through univariate and multivariate logistic regression analyses, we suggest incorporating additional relevant factors. These include socio-economic status,<span><sup>3</sup></span> lifestyle factors<span><sup>4</sup></span> and chronic comorbidities<span><sup>5</sup></span> to better tailor intervention strategies.</p><p>Given the significant differences in healthcare policies, resource allocation, socio-economic conditions and patient education across different countries, conducting subgroup analyses by country or centre is particularly important.<span><sup>6</sup></span> This approach would allow for a more precise assessment of regional disparities and provide a stronger basis for developing targeted interventions. For instance, in regions with limited healthcare resources, interventions may need to focus more on community-level support and education.</p><p>Moreover, as populations age, effective collaboration between social workers and clinicians is essential for providing comprehensive care to elderly patients, especially in managing complex health issues such as DGBI. Individually, social workers can conduct mental health assessments to identify anxiety and depression in elderly patients with DGBIs and collaborate with clinicians to develop treatment plans that include psychological interventions. At the community level, social workers and clinicians should jointly deliver health education, raise awareness of DGBI, and connect patients with community resources such as support groups and counselling services to ensure continuous social support and psychological care. At the policy level, social workers can work with policymakers and healthcare providers to advocate for more comprehensive public health strategies, including increased focus and resources for DGBIs in the elderly population.</p><p>In summary, Sperber et al have provided valuable insights int
我们对 Sperber 等人最近的一项研究1 很感兴趣,该研究探讨了肠脑互动障碍 (DGBI) 在老年人群中的发病率和临床意义。研究发现,尽管老年患者的患病率低于年轻人,但他们仍然面临着巨大的健康负担,尤其是在大便失禁方面。尽管该研究提供了宝贵的见解,但我们认为仍有需要改进的地方。首先,尽管作者努力减少数据缺失,但这仍然是一个不可避免的问题,可能会影响结果的准确性和可靠性。这一问题在老年人群中尤为突出,因为在老年人群中,回忆偏差和社会期望偏差等报告偏差可能更为明显。2 其次,尽管该研究通过单变量和多变量逻辑回归分析对年龄、性别、地理区域和症状严重程度等关键变量进行了有效调整,但我们建议纳入更多相关因素。鉴于不同国家在医疗政策、资源分配、社会经济条件和患者教育等方面存在显著差异,按国家或中心进行分组分析尤为重要。例如,在医疗资源有限的地区,干预措施可能需要更加注重社区层面的支持和教育。此外,随着人口老龄化,社工和临床医生之间的有效合作对于为老年患者提供全面护理至关重要,尤其是在管理 DGBI 等复杂的健康问题时。就个人而言,社工可以进行心理健康评估,以识别患有 DGBI 的老年患者的焦虑和抑郁情况,并与临床医生合作制定包括心理干预在内的治疗计划。在社区层面,社工和临床医生应共同开展健康教育,提高人们对深部神经损伤的认识,并为患者联系社区资源,如支持小组和咨询服务,以确保持续的社会支持和心理护理。在政策层面,社工可以与政策制定者和医疗服务提供者合作,倡导更全面的公共卫生策略,包括增加对老年人群DGBIs的关注和资源投入。通过进一步优化数据处理、纳入更多混杂因素、进行亚组分析以及加强多学科合作,未来的研究和实践可以更有效地应对DGBIs带来的挑战,最终改善老年人群的生活质量:方法学;形式分析;写作-原稿。魏华:方法论;写作--原稿。刘明:构思;方法;指导;写作-审阅和编辑。本研究未获得任何资助。作者声明与本工作无利益冲突。要查看这些文章,请访问 https://doi.org/10.1111/apt.18103 和 https://doi.org/10.1111/apt.18252。
{"title":"Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations","authors":"Rui Zhang,&nbsp;Hua Wei,&nbsp;Ming Liu","doi":"10.1111/apt.18225","DOIUrl":"10.1111/apt.18225","url":null,"abstract":"&lt;p&gt;We were interested in the recent study by Sperber et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; This explored the prevalence and clinical significance of disorders of gut–brain interaction (DGBI) in the elderly population. It found that despite a lower prevalence than in younger populations, elderly patients still face a significant health burden, particularly with regard to faecal incontinence. Although the study provided valuable insights, we believe that there are still areas for improvement.&lt;/p&gt;&lt;p&gt;First, despite the authors' efforts to minimise missing data, it remains an unavoidable issue that could impact the accuracy and reliability of the results. This concern is particularly relevant in older populations, where reporting biases such as recall bias and social desirability bias may be more pronounced. We recommend the use of multiple imputation and sensitivity analyses to mitigate these biases and strengthen the robustness of the findings.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Second, although the study effectively adjusted for key variables such as age, gender, geographic region and symptom severity through univariate and multivariate logistic regression analyses, we suggest incorporating additional relevant factors. These include socio-economic status,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; lifestyle factors&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; and chronic comorbidities&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; to better tailor intervention strategies.&lt;/p&gt;&lt;p&gt;Given the significant differences in healthcare policies, resource allocation, socio-economic conditions and patient education across different countries, conducting subgroup analyses by country or centre is particularly important.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; This approach would allow for a more precise assessment of regional disparities and provide a stronger basis for developing targeted interventions. For instance, in regions with limited healthcare resources, interventions may need to focus more on community-level support and education.&lt;/p&gt;&lt;p&gt;Moreover, as populations age, effective collaboration between social workers and clinicians is essential for providing comprehensive care to elderly patients, especially in managing complex health issues such as DGBI. Individually, social workers can conduct mental health assessments to identify anxiety and depression in elderly patients with DGBIs and collaborate with clinicians to develop treatment plans that include psychological interventions. At the community level, social workers and clinicians should jointly deliver health education, raise awareness of DGBI, and connect patients with community resources such as support groups and counselling services to ensure continuous social support and psychological care. At the policy level, social workers can work with policymakers and healthcare providers to advocate for more comprehensive public health strategies, including increased focus and resources for DGBIs in the elderly population.&lt;/p&gt;&lt;p&gt;In summary, Sperber et al have provided valuable insights int","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18225","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply 信:膳食乳化剂与肠道健康--一个不断发展的故事的开端:作者回复。
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-08 DOI: 10.1111/apt.18267
Jessica A. Fitzpatrick, Peter R. Gibson, Emma P. Halmos
<p>We thank Dr Li for comments<span><sup>1</sup></span> on our study that described the first evaluation of diets high and low in emulsifiers added to the food supply on intestinal barrier function in healthy adults.<span><sup>2</sup></span> Dr Li introduced two aspects—the conduct of the study and its generalisability. The criticisms of conduct, specifically how dietary adherence was assessed, where nearly all food was supplied and food diaries kept, is unfounded. We agree that single blinding was a limitation, but not likely to be associated with much bias since end points were objective.</p><p>Dr Li's suggestion of examining the role of dietary emulsifiers among a larger and more diverse cohort for generalisability, which is important for making broad clinical practice recommendations, is premature and likely to dilute important data that can be gathered only from the highly controlled interventions provided to a targeted cohort. Our study was exploratory, attempting to provide proof-of-concept. Understanding a novel research question that had not been previously posed requires a stepwise programme. The pilot observations can indeed completely change the nature of that programme.</p><p>Preclinical findings led to the concept that emulsifiers added to our food supply are detrimental to intestinal health,<span><sup>3</sup></span> but their effect has not been established in humans. We have developed a stepwise programme that aims to understand the true effect of emulsifiers in Crohn's disease. Step 1 was an analysis of the published literature.<span><sup>4</sup></span> We discovered several key facts that were not well understood by researchers. For example, the term, ‘emulsifiers’, has been incorrectly applied to thickeners without surface-acting properties (such as carboxymethyl cellulose) and to polysaccharides that do neither (such as maltodextrin). In Step 2, we created a database of emulsifiers in the food supply in Australia and found that those studied in preclinical trials were not ubiquitous in the food supply as advertised and had been evaluated in huge doses with little relevance to exposure in the diet.<span><sup>5</sup></span> From the database, we developed experimental diets that met heathy eating guidelines, but differed only in emulsifier content for use in clinical trials.<span><sup>5</sup></span> These diets were palatable and tolerable.<span><sup>5</sup></span> In Step 3, we studied effects in healthy humans.<span><sup>2</sup></span> The high, but not low, emulsifier diet was associated with improved barrier function when tested in a resting, unstressed, fasting state,<span><sup>2</sup></span> but enhanced the impairment of barrier function induced by corticotropin-releasing factor (CRH), a model of acute stress.<span><sup>6</sup></span> In contrast, low emulsifier intake provided durable protection from this effect.<span><sup>2</sup></span> Such observations open issues of the association with emulsifier intake and innate i
我们感谢李博士对我们的研究发表的评论1,该研究首次评估了在食物中添加高乳化剂和低乳化剂的饮食对健康成年人肠道屏障功能的影响。对研究行为的批评,特别是对如何评估饮食依从性的批评是毫无根据的。李博士建议在更大范围、更多样化的人群中研究膳食乳化剂的作用,以获得可推广性,这对于提出广泛的临床实践建议非常重要,但这一建议还为时过早,而且很可能会冲淡只能从为目标人群提供的高度可控干预措施中收集到的重要数据。我们的研究是探索性的,试图提供概念验证。要理解一个以前从未提出过的新研究问题,需要一个循序渐进的方案。临床前研究发现,食品中添加的乳化剂会损害肠道健康3 ,但其对人体的影响尚未得到证实。我们制定了一项循序渐进的计划,旨在了解乳化剂对克罗恩病的真正影响。第 1 步是对已发表的文献进行分析。4 我们发现了研究人员不太了解的几个关键事实。例如,"乳化剂 "一词被错误地应用于不具有表面活性的增稠剂(如羧甲基纤维素)和不具有表面活性的多糖(如麦芽糊精)。在步骤 2 中,我们建立了澳大利亚食品供应中乳化剂的数据库,发现在临床前试验中研究过的乳化剂并不像宣传的那样在食品供应中无处不在,而且评估的剂量很大,与膳食中的暴露量关系不大。2 在静息、非应激、空腹状态下进行测试时,高乳化剂饮食(而非低乳化剂饮食)与屏障功能的改善有关,2 但会增强促肾上腺皮质激素释放因子(CRH)(一种急性应激模型)对屏障功能的损害。6 第四步是在活动性克罗恩病患者中测试这些饮食(ACTRN12619000980134)。因此,正如李博士1 正确指出的那样,我们的试点工作除了有助于引导未来的研究方向之外,几乎没有提供任何答案,但却为妖魔化乳化剂的科学依据打上了一个大大的问号。在这条研究道路上,开展针对多种疾病状态的长期研究或提出膳食建议还为时尚早:构思;写作--审阅和编辑。Peter R. Gibson:构思;写作--审阅和编辑。Emma P. Halmos:JAF:无。PRG:担任 Anatara、Atmo Biosciences、Topas 和 Comvita 的顾问或咨询委员会成员;从 Atmo Biosciences 和 Mindset Health 获得研究人员驱动研究的研究补助金;从 Dr Falk Pharma 和 Mindset Health Pty Ltd. 获得演讲酬金;是 Atmo Biosciences 的股东。EPH:获得 Mindset Health Pty Ltd 和澳大利亚胃肠病学会 IBD 临床项目奖的研究资助。她曾为Ferring、Janssen、Abbvie、Takeda、Shire、Sandoz和Dr Falk Pharma等公司提供酬金或咨询。要查看这些文章,请访问 https://doi.org/10.1111/apt.18172 和 https://doi.org/10.1111/apt.18226。
{"title":"Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply","authors":"Jessica A. Fitzpatrick,&nbsp;Peter R. Gibson,&nbsp;Emma P. Halmos","doi":"10.1111/apt.18267","DOIUrl":"10.1111/apt.18267","url":null,"abstract":"&lt;p&gt;We thank Dr Li for comments&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; on our study that described the first evaluation of diets high and low in emulsifiers added to the food supply on intestinal barrier function in healthy adults.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Dr Li introduced two aspects—the conduct of the study and its generalisability. The criticisms of conduct, specifically how dietary adherence was assessed, where nearly all food was supplied and food diaries kept, is unfounded. We agree that single blinding was a limitation, but not likely to be associated with much bias since end points were objective.&lt;/p&gt;&lt;p&gt;Dr Li's suggestion of examining the role of dietary emulsifiers among a larger and more diverse cohort for generalisability, which is important for making broad clinical practice recommendations, is premature and likely to dilute important data that can be gathered only from the highly controlled interventions provided to a targeted cohort. Our study was exploratory, attempting to provide proof-of-concept. Understanding a novel research question that had not been previously posed requires a stepwise programme. The pilot observations can indeed completely change the nature of that programme.&lt;/p&gt;&lt;p&gt;Preclinical findings led to the concept that emulsifiers added to our food supply are detrimental to intestinal health,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; but their effect has not been established in humans. We have developed a stepwise programme that aims to understand the true effect of emulsifiers in Crohn's disease. Step 1 was an analysis of the published literature.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; We discovered several key facts that were not well understood by researchers. For example, the term, ‘emulsifiers’, has been incorrectly applied to thickeners without surface-acting properties (such as carboxymethyl cellulose) and to polysaccharides that do neither (such as maltodextrin). In Step 2, we created a database of emulsifiers in the food supply in Australia and found that those studied in preclinical trials were not ubiquitous in the food supply as advertised and had been evaluated in huge doses with little relevance to exposure in the diet.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; From the database, we developed experimental diets that met heathy eating guidelines, but differed only in emulsifier content for use in clinical trials.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; These diets were palatable and tolerable.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; In Step 3, we studied effects in healthy humans.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The high, but not low, emulsifier diet was associated with improved barrier function when tested in a resting, unstressed, fasting state,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; but enhanced the impairment of barrier function induced by corticotropin-releasing factor (CRH), a model of acute stress.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; In contrast, low emulsifier intake provided durable protection from this effect.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Such observations open issues of the association with emulsifier intake and innate i","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Association between terlipressin and multidrug-resistant organism rectal colonization: Authors' reply 信特利加压素与耐多药生物直肠定植之间的关系:作者回复。
IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-05 DOI: 10.1111/apt.18256
Marcus M. Mücke, Wenyi Gu, Javier Fernandez, Jonel Trebicka
<p>We read with great interest the letter to the editors by Tan et al.<span><sup>1</sup></span> discussing our study<span><sup>2</sup></span> and their own findings concerning the impact of terlipressin on colonization of multidrug-resistant bacteria (MDRO) in patients with decompensated liver cirrhosis. In our study, apart from the well-known risk factor of antibiotic therapy, terlipressin administered in the previous 14 days was the only independent pharmaceutical agent associated with MDRO colonization. Similarly, Tan et al. observed a significant association of terlipressin therapy with the detection of MDRO colonization in univariate analysis. However, in multivariate analysis, when considering other risk factors, such as prior detection of (the same) MDRO in the last 365 days before liver transplantation, terlipressin was only borderline significant associated with vancomycin-resistant <i>Enterococcus</i> spp. (HR 2.0, <i>p</i> = 0.06) and not significant with MDR Gram-negative (GN) bacteria (HR 2.2, <i>p</i> = 0.09) colonization. More surprisingly, in the multivariate analysis also the antibiotic therapy was not associated with MDRO colonization. This raises doubts about the selection of the population in this study. Indeed, this was a highly selected patient collective of 594 liver transplant recipients. Being on the waiting list for liver transplant implies that patients had an intensive health care contact (clinical decompensations, diagnostic/therapeutic procedures). By contrast, our data are based in ‘all comers’ in an acute decompensation from a training cohort, validation cohort and international external cohort with in total almost 656 patients.</p><p>We agree with the authors, for patients with advanced liver disease and previous health care exposure such as antibiotic therapy, hospitalization or ICU admission constitute important risk factors to favour MDRO colonization. In our study, these commonly accepted risk factors equally distributed among both the groups with and without terlipressin treatment in all three cohorts. Additionally, we carefully considered all risk factors in our analyses and even matched cohorts according to disease severity and antibiotic therapy as well as other potential confounders while matching was not performed in the cohort of Tan et al.</p><p>In their cohort prior colonization with (the same) MDRO was the strongest independent risk factor in multivariate analysis. Because of that, the authors proposed to focus on patients' history and MDRO risk factors. Indeed, MDRO risk factors, including prior MDRO colonization, were extensively considered in our study and consecutive analyses. Only patients with a new MDRO isolation resulting from rectal MDRO screening were considered as (de novo) colonized patients. Thus, all patients with previous known and similar MDRO were not considered as (de novo) colonized. Accordingly, previous MDRO colonization with the same/a similar MDRO could neither be a confounder
我们饶有兴趣地阅读了 Tan 等人1 致编辑的信,信中讨论了我们的研究2 以及他们自己关于特利加压素对肝硬化失代偿期患者耐多药细菌(MDRO)定植的影响的研究结果。在我们的研究中,除了众所周知的抗生素治疗这一风险因素外,在过去 14 天内使用特利加压素是唯一与 MDRO 定植相关的独立药物。同样,Tan 等人在单变量分析中也观察到特利加压素治疗与 MDRO 定植检测有显著关联。然而,在多变量分析中,当考虑到其他风险因素(如肝移植前365天内曾检测到(相同的)MDRO)时,特利加压素与耐万古霉素肠球菌属(HR 2.0,p = 0.06)的相关性仅为边缘显著,而与耐多药革兰氏阴性(GN)菌(HR 2.2,p = 0.09)定植的相关性则不显著。更令人惊讶的是,在多变量分析中,抗生素治疗也与 MDRO 定植无关。这让人对该研究的人群选择产生了怀疑。事实上,这是一个由 594 名肝移植受者组成的高选择性患者群体。列入肝移植候选名单意味着患者有密集的医疗接触(临床失代偿、诊断/治疗过程)。我们同意作者的观点,对于晚期肝病患者和既往接触过抗生素治疗、住院或入住重症监护室等医护人员的患者来说,这些都是有利于MDRO定植的重要风险因素。在我们的研究中,这些普遍接受的风险因素在所有三个队列中接受特利加压素治疗和未接受特利加压素治疗的两组患者中平均分布。此外,我们在分析中仔细考虑了所有风险因素,甚至根据疾病严重程度和抗生素治疗以及其他潜在混杂因素对队列进行了配对,而在 Tan 等人的队列中没有进行配对。因此,作者建议重点关注患者的病史和 MDRO 风险因素。事实上,在我们的研究和连续分析中,MDRO 风险因素,包括之前的 MDRO 定植,都得到了广泛的考虑。只有在直肠MDRO筛查中新分离出MDRO的患者才被视为(新)定植患者。因此,所有曾感染过已知和类似 MDRO 的患者都不被视为(新)定植患者。总之,Tan 等人的数据支持了我们的研究结果,即特利加压素似乎与 MDRO 定植有关,而 MDRO 定植是肝硬化患者的一个相关问题。应考虑MDRO感染的多种风险因素。有必要开展进一步研究--最好是随机对照试验--以揭示这些风险因素(包括特利加压素的使用)各自的作用和相互影响:构思;调查;写作-原稿;写作-审阅和编辑。顾文怡写作--审阅和编辑。哈维尔-费尔南德斯(Javier Fernandez):构思;写作--原稿;写作--审阅和编辑;指导。Jonel Trebicka:指导;构思;调查;写作--原稿;写作--审阅和编辑。Jonel Trebicka得到了德国研究基金会(DFG)项目编号403224013-SFB 1382 (A09)、德国联邦教育和研究部(BMBF)DEEP-HCC项目以及黑森州高等教育、研究和艺术部(HMWK)ENABLE和ACLF-I集群项目的支持。MICROB-PREDICT(项目编号825694)、DECISION(项目编号847949)、GALAXY(项目编号668031)、LIVERHOPE(项目编号731875)和IHMCSA(项目编号964590)项目获得了欧盟地平线2020研究与创新计划的资助。手稿仅反映作者的观点,欧盟委员会不对使用手稿中的任何信息负责。资助方对研究设计、数据收集和分析、发表决定或手稿撰写没有任何影响。本文与 Mücke 等人的论文相关联。要查看这些文章,请访问 https://doi.org/10.1111/apt.17899 和 https://doi.org/10.1111/apt.18200。
{"title":"Letter: Association between terlipressin and multidrug-resistant organism rectal colonization: Authors' reply","authors":"Marcus M. Mücke,&nbsp;Wenyi Gu,&nbsp;Javier Fernandez,&nbsp;Jonel Trebicka","doi":"10.1111/apt.18256","DOIUrl":"10.1111/apt.18256","url":null,"abstract":"&lt;p&gt;We read with great interest the letter to the editors by Tan et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; discussing our study&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and their own findings concerning the impact of terlipressin on colonization of multidrug-resistant bacteria (MDRO) in patients with decompensated liver cirrhosis. In our study, apart from the well-known risk factor of antibiotic therapy, terlipressin administered in the previous 14 days was the only independent pharmaceutical agent associated with MDRO colonization. Similarly, Tan et al. observed a significant association of terlipressin therapy with the detection of MDRO colonization in univariate analysis. However, in multivariate analysis, when considering other risk factors, such as prior detection of (the same) MDRO in the last 365 days before liver transplantation, terlipressin was only borderline significant associated with vancomycin-resistant &lt;i&gt;Enterococcus&lt;/i&gt; spp. (HR 2.0, &lt;i&gt;p&lt;/i&gt; = 0.06) and not significant with MDR Gram-negative (GN) bacteria (HR 2.2, &lt;i&gt;p&lt;/i&gt; = 0.09) colonization. More surprisingly, in the multivariate analysis also the antibiotic therapy was not associated with MDRO colonization. This raises doubts about the selection of the population in this study. Indeed, this was a highly selected patient collective of 594 liver transplant recipients. Being on the waiting list for liver transplant implies that patients had an intensive health care contact (clinical decompensations, diagnostic/therapeutic procedures). By contrast, our data are based in ‘all comers’ in an acute decompensation from a training cohort, validation cohort and international external cohort with in total almost 656 patients.&lt;/p&gt;&lt;p&gt;We agree with the authors, for patients with advanced liver disease and previous health care exposure such as antibiotic therapy, hospitalization or ICU admission constitute important risk factors to favour MDRO colonization. In our study, these commonly accepted risk factors equally distributed among both the groups with and without terlipressin treatment in all three cohorts. Additionally, we carefully considered all risk factors in our analyses and even matched cohorts according to disease severity and antibiotic therapy as well as other potential confounders while matching was not performed in the cohort of Tan et al.&lt;/p&gt;&lt;p&gt;In their cohort prior colonization with (the same) MDRO was the strongest independent risk factor in multivariate analysis. Because of that, the authors proposed to focus on patients' history and MDRO risk factors. Indeed, MDRO risk factors, including prior MDRO colonization, were extensively considered in our study and consecutive analyses. Only patients with a new MDRO isolation resulting from rectal MDRO screening were considered as (de novo) colonized patients. Thus, all patients with previous known and similar MDRO were not considered as (de novo) colonized. Accordingly, previous MDRO colonization with the same/a similar MDRO could neither be a confounder ","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18256","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Alimentary Pharmacology & Therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1